|
Emerging new therapeutic applications of capecitabine as a first-line chemotherapeutic agent in the management of advanced carcinomas other than colorectal carcinomaDOI: http://dx.doi.org/10.2147/CMAR.S31907 Keywords: Emerging new therapeutic applications of capecitabine as a first-line chemotherapeutic agent in the management of advanced carcinomas other than colorectal carcinoma Letter (2145) Total Article Views Authors: Kapoor S Published Date May 2012 Volume 2012:4 Pages 129 - 130 DOI: http://dx.doi.org/10.2147/CMAR.S31907 Received: 18 March 2012 Accepted: 19 March 2012 Published: 08 May 2012 Shailendra Kapoor Richmond, VA, USA I read with great interest the recent article by Hameed et al in a recent issu Abstract: Emerging new therapeutic applications of capecitabine as a first-line chemotherapeutic agent in the management of advanced carcinomas other than colorectal carcinoma Letter (2145) Total Article Views Authors: Kapoor S Published Date May 2012 Volume 2012:4 Pages 129 - 130 DOI: http://dx.doi.org/10.2147/CMAR.S31907 Received: 18 March 2012 Accepted: 19 March 2012 Published: 08 May 2012 Shailendra Kapoor Richmond, VA, USA I read with great interest the recent article by Hameed et al in a recent issue of your journal.1 The article is very interesting. Interestingly, the past few years have seen the emergence of capecitabine as a highly potent first-line chemotherapeutic agent against advanced systemic carcinomas other than colorectal carcinoma. For instance, capecitabine has recently been used successfully as a first-line monotherapeutic agent for HER-2-negative metastatic breast cancer.2 Cotherapy with agents such as sorafenib and paclitaxel for HER-2-negative metastatic breast cancer has also been recently used first-line, and significantly improves progressionfree survival, in addition to being very safe.3,4 Similarly, in patients with advanced gastric carcinoma, capecitabine has been used successfully as first-line therapy in combination with agents such as cisplatin.5 The XELOX regimen comprising capecitabine in conjunction with oxaliplatin is another recent highly effective alternative for gastric carcinoma.6 The modified XELIRI regimen compromising capecitabine and irinotecan is a further option for advanced and unresectable gastric carcinoma.7 View original paper by Hameed and colleagues. Post to: Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter Readers of this article also read: Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes The cognitive basis of diglossia in Arabic: Evidence from a repetition priming study within and between languages Morgellons disease: Analysis of a population with clinically confirmed microscopic subcutaneous fibers of unknown etiology Epigenomics in cancer management Amino acid-responsive Crohn's disease: a case study Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease Eye malformations in Cameroonian children: a clinical survey Dexmedetomidine sedation in painful posterior segment surgery
|